Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Janelle Hart

Managing Editor, Custom Content

Boston, MA
Janelle is an experienced writer and editor with a background in health care communications and journalism. She currently produces custom content across an array of mediums and platforms that focuses on pharmaceutical and biotechnology news and insights. In addition, she contributes to Citeline’s flagship content, such as Scrip Asia 100, Outlook and In Vivo’s Rising Leaders series. Janelle received a dual bachelor’s degree in English and Media and Culture from Miami University and is currently pursuing a master’s degree in Publishing and Writing from Emerson College in Boston, where she currently resides.

Latest From Janelle Hart

DISCO Pharma’s Surfaceome Technology Unlocks Novel Cancer-Selective Targets

Roman Thomas, co-founder and CEO of DISCO Pharmaceuticals, outlines how the company’s surfaceome technology could disrupt drug discovery in oncology.

Rising Leaders Innovation

Exeliom’s Bacteria-Focused Approach To Immunotherapy

In Vivo sat down with Benjamin Hadida, CEO of Exeliom, at the 2024 BIO International Convention to discuss how the company is using its first-in-class drug candidate to improve therapeutic responsiveness in immuno-oncology, immuno-inflammation and rare disease. 

Innovation Financing

Secarna Addresses Undruggable Targets With Antisense Platform

At the 2024 BIO International Convention, In Vivo spoke with Secarna Pharmaceuticals' CEO Alexander Gebauer about how the biotech's next-gen antisense oligonucleotide technology aims to benefit patients across multiple indications. 

Companies Research & Development

How Cellino’s Cassette Technology Will Impact Regenerative Medicine

Co-founder and CEO of Cellino Biotech, Nabiha Saklayen, discusses the company’s innovative platform which uses automated technologies to overcome challenges in the development of regenerative medicine.

Rising Leaders Regenerative Medicine

Cutiss’ Approach To Skin Engineering

CUTISS co-founder and CEO Daniela Marino shares insights with In Vivo about the future of regenerative medicine and the ongoing development of denovoSkin, a next-generation human skin graft technology.

Rising Leaders Innovation

Next-Gen ADCs: Araris CEO Highlights Potential In Linker Technology

In Vivo sat down with 2023 Rising Leader Philipp Spycher, CEO of Araris Biotech, to discuss trends in antibody-drug conjugate R&D, and how Araris hopes to disrupt today’s chemotherapy treatment paradigm with novel linker technology.

Rising Leaders Innovation
See All
UsernamePublicRestriction

Register